Temprian Oncology
1 known investors
Temprian Oncology develops nanoparticle-based "Supercarriers" that deliver a prodrug toxic to melanoma cells, releasing the active ingredient inside metastatic melanoma tumor cells in low-pH pigment-making organelles. The therapy targets late-stage, metastasized melanoma and is designed to work alongside or replace existing TKI and immune checkpoint inhibitor treatments.
Investors · 1
Frequently asked questions
- What does Temprian Oncology do?
- Temprian Oncology develops nanoparticle-based "Supercarriers" that deliver a prodrug toxic to melanoma cells, releasing the active ingredient inside metastatic melanoma tumor cells in low-pH pigment-making organelles. The therapy targets late-stage, metastasized melanoma and is designed to work alongside or replace existing TKI and immune checkpoint inhibitor treatments.
- Who are Temprian Oncology's investors?
- Temprian Oncology's investors include 2Flo Ventures.